Skye Bioscience Advances Drug Trial to Cohort 2 on Favorable Early Safety Data
SKYE sits 33% above its 52-week low of $0.566 on light trading volume (0.3× avg).
Summary
Skye Bioscience announced that its Cohort Review Committee has approved the opening of Cohort 2 for its clinical trial, based on favorable safety data from the first four participants in Cohort 1. This positive development in the company's drug pipeline provides a much-needed boost, especially following recent negative news including a 10-Q filing detailing deepening losses and a going concern warning, and a Nasdaq delisting notice. For a small biotech company facing significant financial and compliance challenges, any progress in its core product development is material, as it represents a step towards potential future value creation. Traders will be watching for further clinical trial updates, particularly efficacy data, while also monitoring the company's efforts to address its financial stability and Nasdaq listing status.
At the time of this announcement, SKYE was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.5M. The 52-week trading range was $0.57 to $5.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.